title: NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections.
abstract: We established a new field clone of Plasmodium falciparum for use in controlled human malaria infections and vaccine studies to complement the current small portfolio of P. falciparum strains, primarily based on NF54. The Cambodian clone NF135.C10 consistently produced gametocytes and generated substantial numbers of sporozoites in Anopheles mosquitoes and diverged from NF54 parasites by genetic markers. In a controlled human malaria infection trial, 3 of 5 volunteers challenged by mosquitoes infected with NF135.C10 and 4 of 5 challenged with NF54 developed parasitemia as detected with microscopy. The 2 strains induced similar clinical signs and symptoms as well as cellular immunological responses.
  
  
  BACKGROUND
  NCT01002833.
authors.affiliation: Department of Medical Microbiology, Radboud University Nijmegen Medical Center, the Netherlands.
authors.forename: Anne C
authors.initials: AC
authors.lastname: Teirlinck
authors.forename: Meta
authors.initials: M
authors.lastname: Roestenberg
authors.forename: Marga
authors.initials: M
authors.lastname: van de Vegte-Bolmer
authors.forename: Anja
authors.initials: A
authors.lastname: Scholzen
authors.forename: Moniek J L
authors.initials: MJ
authors.lastname: Heinrichs
authors.forename: Rianne
authors.initials: R
authors.lastname: Siebelink-Stoter
authors.forename: Wouter
authors.initials: W
authors.lastname: Graumans
authors.forename: Geert-Jan
authors.initials: GJ
authors.lastname: van Gemert
authors.forename: Karina
authors.initials: K
authors.lastname: Teelen
authors.forename: Martijn W
authors.initials: MW
authors.lastname: Vos
authors.forename: Krystelle
authors.initials: K
authors.lastname: Nganou-Makamdop
authors.forename: Steffen
authors.initials: S
authors.lastname: Borrmann
authors.forename: Yolanda P A
authors.initials: YP
authors.lastname: Rozier
authors.forename: Marianne A A
authors.initials: MA
authors.lastname: Erkens
authors.forename: Adrian J F
authors.initials: AJ
authors.lastname: Luty
authors.forename: Cornelus C
authors.initials: CC
authors.lastname: Hermsen
authors.forename: B Kim Lee
authors.initials: BK
authors.lastname: Sim
authors.forename: Lisette
authors.initials: L
authors.lastname: van Lieshout
authors.forename: Stephen L
authors.initials: SL
authors.lastname: Hoffman
authors.forename: Leo G
authors.initials: LG
authors.lastname: Visser
authors.forename: Robert W
authors.initials: RW
authors.lastname: Sauerwein
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D000852:Anopheles / Q000469:parasitology; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use*; D053626:Atovaquone / Q000008:administration & dosage / Q000627:therapeutic use; D005838:Genotype; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology / Q000503:physiopathology*; D018512:Parasitemia / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology / Q000503:physiopathology*; D010963:Plasmodium falciparum / Q000187:drug effects / Q000235:genetics / Q000254:growth & development / Q000472:pathogenicity*; D002727:Proguanil / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000962:Antimalarials; D002727:Proguanil; D053626:Atovaquone